Medizinische Universität Graz - Research portal
Selected Publication:
Bonelli, RM; Mayr, BM; Niederwieser, G; Reisecker, F; Kapfhammer, HP.
Ziprasidone in Huntington's disease: the first case reports.
J Psychopharmacol. 2003; 17(4):459-460
Doi: 10.1177%2F0269881103174009
(- Case Report)
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Bonelli Raphael
- Co-authors Med Uni Graz
- Kapfhammer Hans-Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Huntington's disease (HD) is a relentlessly progressive neuropsychiatric disorder with an underlying autosomal dominantly inherited genetic defect. Classical antipsychotics (i.e. phenothiazines or butyrophenones) are the most used medication to reduce the (probably dopamine-born) choreiform hyperkinesias. Ziprasidone is the latest of a new class of atypical antipsychotics; it has not been studied so far in this indication. We report three genetically confirmed HD patients who improved significantly in several categories of the motor scale of the Unified HD Rating Scale.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Dopamine Antagonists - therapeutic use
- Female - therapeutic use
- Humans - therapeutic use
- Huntington Disease - drug therapy
- Male - drug therapy
- Middle Aged - drug therapy
- Piperazines - therapeutic use
- Thiazoles - therapeutic use
- Find related publications in this database (Keywords)
- antipsychotic medications
- chorea
- Huntington's disease
- UHDRS
- Ziprasidone